← Back to Dashboard

Foscarnet

Pyrophosphate analog DNA polymerase inhibitor

2D Structure

Loading structure...

3D Structure

Loading 3D structure...

Chemical Identifiers

C(=O)(O)P(=O)(O)O
ZJAOAACCNHFJAH-UHFFFAOYSA-N

Clinical Development by Virus12

Human betaherpesvirus 5
CMV
Target: Viral DNA pol
FDA approved
Preclinical
Phase 2unknown
Phase 3
Approved
FDAJapan
Herpes simplex virus (HSV)
HSV
Target: DNA polymerase UL30
FDA approved
Preclinical
Phase 2positive
Phase 3positive
Approved
FDAJapan
Approval ref: AntiviralDbApproval ref (pmda.go.jp)
Human alphaherpesvirus 3
VZV
Target: Viral DNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Human alphaherpesvirus 1
HSV-1
Target: Viral DNA pol
FDA approved
Preclinical
Phase 2positive
Phase 3positive
Approved
FDAJapan
Human alphaherpesvirus 2
HSV-2
Target: Viral DNA pol
FDA approved
Preclinical
Phase 2positive
Phase 3positive
Approved
FDAJapan
Hepatitis B virus
HBV
Target: Viral RT
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Human gammaherpesvirus 4
EBV
Target: Viral DNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Influenza A virus
FLUAV
Target: Viral DNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Human betaherpesvirus 6
HHV-6
Target: Viral DNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Human gammaherpesvirus 8
KSHV
Target: Viral DNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Rotavirus A
RoV-SA11
Target: Viral RNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan
Indiana vesiculovirus
VSV
Target: Viral RNA pol
Approved (other)
Preclinical
Phase 2
Phase 3
Approved
Japan